Veraxa Biotech Holding AG

VRXA

NASDAQHealthcareBiotechnology

GoAI で開く

前日終値

$1.95

+$0.06 · +3.17%

8月21日 16:00 ET

市場前

$2.00

+$0.05 · +2.56%

8月24日 4:00 ET

日中の時刻はETです。市場データは遅延する場合があります。

企業プロフィール

業界: Biotechnology
セクター: Healthcare
本社: DE

市場での位置

日中レンジ

現在 $1.95

$1.86$2.00

52週レンジ

現在 $1.95

$1.70$27.36

始値: $1.86
前日終値: $1.89
出来高: 8.02万
時価総額: 2.76億 USD
50日平均: $3.5715; 平均以下（-45.40%）
200日平均: $9.2316; 平均以下（-78.88%）

VRXA ニュース

globenewswire.com2026年7月29日

VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates

ZURICH, SWITZERLAND, July 29, 2026 (GLOBE NEWSWIRE) -- VE RAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today provided an update on its core patent portfolio. During…

ソースを読む

globenewswire.com2026年7月27日

VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb

VERAXA Biotech's and OmniAb's bispecific ADC program VXA-222 advances into next phase at VERAXA following the achievement of a key technical milestone.

ソースを読む

globenewswire.com2026年7月27日

VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb

ZURICH, SWITZERLAND, July 27, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies, today announced the advancement of bispecific ADC (bsADC) program…

ソースを読む

globenewswire.com2026年7月24日

VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth

ZURICH, SWITZERLAND , July 24, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in the design and development of next-generation cancer therapeutics, held an Extraordinary General…

ソースを読む

globenewswire.com2026年7月23日

VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio

ZURICH, SWITZERLAND, July 23, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the appointment of Christoph Erkel, Ph.D., as…

ソースを読む

globenewswire.com2026年7月20日

VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan

ZURICH, SWITZERLAND – July 20, 2026 – VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA), an emerging leader in designing novel cancer therapies, today announced that it has received Scientific Advice from the German regulatory…

ソースを読む